Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine Versus Midazolam for Continuous Sedation in the Intensive Care Unit (ICU)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years and over~* Clinical need for sedation of an initially intubated (or tracheotomised) and ventilated (with inspiratory assistance) patient~* Prescribed light to moderate sedation (target RASS = 0 to -3) using midazolam infusion~* Patients should be randomised within 72 hours from ICU admission and within 48 hours of commencing continuous sedation in the ICU~* Patients should have an expected requirement for sedation of at least 24 hours from time of randomisation~* Written informed consent must be obtained according to local regulations before starting any study procedures other than pre-screening.~Exclusion Criteria:~* Acute severe intracranial or spinal neurological disorder due to vascular causes, infection, intracranial expansion or injury~* Uncompensated acute circulatory failure at time of randomisation (severe hypotension with MAP \< 55 mmHg despite volume and pressors)~* Severe bradycardia (HR \< 50 beats/min)~* AV-conduction block II-III (unless pacemaker installed)~* Severe hepatic impairment (bilirubin \> 101 µmol/L)~* Need for muscle relaxation at the time of randomisation (may only be used for intubation and initial stabilization)~* Loss of hearing or vision, or any other condition which would significantly interfere with the collection of study data~* Burn injuries requiring regular anaesthesia or surgery~* Use of centrally acting α2 agonists or antagonists at the time of randomisation, notably clonidine (see section 5.7 for prior and concomitant treatments)~* Known allergy to any of the study drugs or any excipients of the study drugs~* Patients who have or are expected to have treatment withdrawn or withheld due to poor prognosis~* Patients receiving sedation for therapeutic indications rather than to tolerate the ventilator (e.g. epilepsy)~* Patients unlikely to require continuous sedation during mechanical ventilation (e.g. Guillain-Barré syndrome)~* Patients who are unlikely to be weaned from mechanical ventilation; e.g. diseases/injuries primarily affecting the neuromuscular function of the respiratory apparatus such as clearly irreversible disease requiring prolonged ventilatory support (e.g. high spinal cord injury or advanced amyotrophic lateral sclerosis)~* Distal paraplegia~* Positive pregnancy test or currently lactating~* Received any investigational drug within the preceding 30 days~* Concurrent participation in any other interventional study (any study in which patients are allocated to different treatment groups and/or non-routine diagnostic or monitoring procedures are performed)~* Previous participation in this study~* Any other condition which, in the investigator's opinion, would make it detrimental for the subject to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Dexmedetomidine
- 2 (Type: ACTIVE_COMPARATOR): Midazolam

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete